About the Cardiopulmonary Autotransfusion Systems Market
Autotransfusion involves the collection of blood before surgeries and its transfusion during cardiac operations. This procedure is processed in autotransfusion systems that help minimize blood loss by collecting and filtering the RBCs, and reinfusing the blood into an individual. Autotransfusion is an autologous technology involving the retransfusion of a person's own blood, which increases the need for traditional centrifuge devices for separating the RBCs from the blood. Advances in technology have led companies to integrate ultrafiltration technique for blood collection. For instance, Advancis Surgical's ultrafiltration-based HemoSep system can improve patient recovery time by filtering inflammatory molecules, preserving normal clotting function, and maintaining platelet populations.
Technavio’s analysts forecast the global cardiopulmonary autotransfusion systems to grow at a CAGR of 1.91% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global cardiopulmonary autotransfusion systems for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the total consumption of cardiopulmonary autotransfusion systems globally. These systems help reduce the risk of infections that can occur due to the use of allogenic blood.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Cardiopulmonary Autotransfusion Systems Market 2016-2020
Technavio recognizes the following companies as the key players in the global cardiopulmonary autotransfusion systems market: Advancis Surgical, Fresenius Kabi, Haemonetics, LivaNova, Medtronic, and Terumo.
Other Prominent Vendors in the market are: Atrium Medical, Global Blood Resources, Redax, Sarstedt, and Stryker.
Commenting on the report, an analyst from Technavio’s team said: “One trend augmenting the growth of this market is the development of ultrafiltration systems. At present, medical facilities are using three types of ultrafiltration techniques during cardiac surgeries - conventional ultrafiltration, modified ultrafiltration, and zero balance ultrafiltration. Additionally, some vendors are also focusing on developing modified ultrafiltration-based systems. For instance, Global Blood Resources and Advancis Surgical have developed ultrafiltration technique-based HemoBag blood salvage device and HemoSep system, respectively.”
According to the report, one driver that will incite growth in this market is the complications associated with allogenic blood transfusion. Cardiac surgeries are complex and involve the loss of a significant amount of blood during deep surgical incisions. This can lower the balance of blood in the body and increase the risks of surgery-induced anemia in people after surgery. This leads to the demand for a significant volume of blood supply, which depends on the complexity of the surgery.
Further, the report states that the use of allogenic blood transfusion will inhibit the possibilities for growth in this market. Autotransfusion technology was developed to replace allogenic blood transfusion that has many adverse effects. However, many hospitals and ASCs worldwide, particularly in countries in APAC and developing economies such as Brazil, Mexico, India, and China, are still using allogenic blood transfusion despite its known complications. Many people in these countries are unaware of autotransfusion technology and associated systems and benefits.
Advancis Surgical, Fresenius Kabi, Haemonetics, LivaNova, Medtronic, Terumo, Atrium Medical, Global Blood Resources, Redax, Sarstedt, and Stryker.